

Klemens Budde

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6190154/klemens-budde-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

533
papers

18,768
citations

68
h-index

119
g-index

622
ext. papers

22,283
ext. citations

4.7
avg, IF

6.21
L-index

#	Paper	IF	Citations
533	Authors' Reply: SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?. <i>Journal of the American Society of Nephrology: JASN</i> , 2022 ,	12.7	
532	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients.. <i>JCI Insight</i> , 2022 ,	9.9	4
531	Body Mass Index Thresholds and the Use of Bariatric Surgery in the Field of Kidney Transplantation in Germany.. <i>Obesity Surgery</i> , 2022 , 32, 1641	3.7	1
530	Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
529	Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report.. <i>Transplant International</i> , 2022 , 35, 10302	3	0
528	Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.. <i>Trials</i> , 2022 , 23, 270	2.8	1
527	The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation.. <i>PLoS ONE</i> , 2022 , 17, e0266319	3.7	0
526	Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.. <i>Transplant International</i> , 2022 , 35, 10109	3	0
525	Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , 2021 , 7, e778	2.3	3
524	Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. <i>Journal of Critical Care</i> , 2021 , 67, 126-131	4	0
523	Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	4
522	Clinical Outcome Prediction from Admission Notes using Self-Supervised Knowledge Integration 2021 ,		2
521	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	17
520	Sirolimus in renal transplant recipients with malignancies in Germany. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 2047-2058	4.5	2
519	Inosine 5-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. <i>Transplantation</i> , 2021 , 105, 916-927	1.8	5
518	Tuberous Sclerosis registry to increase disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2021 , 12, 630378	4.1	3
517	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3851-3862	3.8	0

516	A 2020 Banff Antibody-mediated Injury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation - a cohort study. <i>Transplant International</i> , 2021 , 34, 488-498	3	5
515	Exploring the Complexity of Death-Censored Kidney Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 1513-1526	12.7	10
514	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200	3.2	17
513	TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients. <i>Journal of Visualized Experiments</i> , 2021 ,	1.6	7
512	Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform. <i>Journal of Visualized Experiments</i> , 2021 ,	1.6	3
511	Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. <i>Kidney International Reports</i> , 2021 , 6, 905-915	4.1	6
510	Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	9
509	Undoubtedly, kidney transplant recipients have a higher mortality due to COVID-19 disease compared to the general population. <i>Transplant International</i> , 2021 , 34, 769-771	3	7
508	Kidney graft function and arterial stiffness in renal transplant recipients. <i>Acta Biochimica Polonica</i> , 2021 , 68, 331-339	2	0
507	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021 , 6,	28	93
506	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021 , 12, 690698	8.4	28
505	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the Tuberous Sclerosis registry to increase disease awareness (TOSCA). <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 301	4.2	3
504	Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2083-2098	12.7	1
503	Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. <i>Transplant International</i> , 2021 , 34, 1542-1552	3	2
502	Impact of Early Pancreatic Graft Loss on Outcome after Simultaneous Pancreas-Kidney Transplantation (SPKT)-A Landmark Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
501	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	91
500	Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity. <i>American Journal of Transplantation</i> , 2021 , 21, 1391-1401	8.7	9
499	eHealth in transplantation. <i>Transplant International</i> , 2021 , 34, 16-26	3	10

498	The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective single-center cohort study. <i>Transplant International</i> , 2021 , 34, 259-271	3	3
497	Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 14-26	3.5	1
496	A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 708-722	12.7	28
495	Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging. <i>American Journal of Transplantation</i> , 2021 , 21, 1725-1739	8.7	1
494	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. <i>PLoS ONE</i> , 2021 , 16, e0245880	3.7	3
493	Aspect-Based Passage Retrieval with Contextualized Discourse Vectors. <i>Lecture Notes in Computer Science</i> , 2021 , 537-542	0.9	1
492	STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL® /Crilomus® in Renal Transplant Recipients - an Observational Study in Germany. <i>Current Clinical Pharmacology</i> , 2021 , 16, 357-368	2.5	
491	What happens after graft loss? A large, long-term, single-center observation. <i>Transplant International</i> , 2021 , 34, 732-742	3	1
490	The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. <i>Genetics in Medicine</i> , 2021 , 23, 1219-1224	8.1	6
489	Clinicopathologic Features and Risk Factors of Proteinuria in Transplant Glomerulopathy. <i>Frontiers in Medicine</i> , 2021 , 8, 666319	4.9	0
488	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. <i>Clinical Immunology</i> , 2021 , 229, 108792	9	0
487	Does the Side Matter? A Retrospective Cohort Study Comparing Left and Right Pure Laparoscopic Donor Nephrectomies. <i>Urologia Internationalis</i> , 2021 , 105, 1076-1084	1.9	1
486	Low-dose rapamycin does not impair vascular integrity and tubular regeneration after kidney transplantation in rats. <i>Scientific Reports</i> , 2021 , 11, 16270	4.9	1
485	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021 , 123, 50-66	2.9	33
484	Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
483	ANALYZING CAUSES FOR DEATH-CENSORED ALLOGRAFT FAILURE IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2020 , 104, S69-S70	1.8	
482	Is a Retroaortic Vein a Risk Factor in Laparoscopic Living Donor Nephrectomy?. <i>Urologia Internationalis</i> , 2020 , 104, 641-645	1.9	1
481	Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2

480	Obesity, Fat Tissue Parameters, and Arterial Stiffness in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2020 , 52, 2341-2346	1.1	3
479	Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
478	Determinants of Successful Use of Sirolimus in Renal Transplant Patients. <i>Transplantation Proceedings</i> , 2020 , 52, 3103-3111	1.1	0
477	Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: A retrospective study. <i>Journal of Critical Care</i> , 2020 , 58, 1-5	4	1
476	Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. <i>Transplantation Reviews</i> , 2020 , 34, 100531	3.3	9
475	Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. <i>Annals of Transplantation</i> , 2020 , 25, e923278	1.4	1
474	De-novo malignancies after kidney transplantation: A long-term observational study. <i>PLoS ONE</i> , 2020 , 15, e0242805	3.7	2
473	Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients. <i>Cardiology Journal</i> , 2020 ,	1.4	1
472	IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 2020 , 104, S314-S315	1.8	
471	THREE-MONTH RESULTS OF A PHASE 2 TRIAL EVALUATING CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION [EARLY IMPACT OF IL-6 BLOCKADE ON DONOR-SPECIFIC ANTIBODY LEVELS, REJECTION MORPHOLOGY AND GENE EXPRESSION. <i>Transplantation</i> , 2020 , 104, S355-S355	1.8	
470	Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2020 , 10,	5.1	3
469	Gesundheits-Apps zur verbesserten Versorgung von Patienten nach Nierentransplantation 2020 , 195-211		
468	The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study. <i>Acta Biochimica Polonica</i> , 2020 , 67, 613-622	2	1
467	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. <i>Kidney International</i> , 2020 , 98, 1044-1052	9.9	35
466	Predictors of graft survival at diagnosis of antibody-mediated renal allograft rejection: a retrospective single-center cohort study. <i>Transplant International</i> , 2020 , 33, 149-160	3	1
465	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020 , 104, 911-922	1.8	74
464	Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients. <i>Transplant Immunology</i> , 2020 , 63, 101333	1.7	3
463	ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION [MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?. <i>Transplantation</i> , 2020 , 104, S67-S67	1.8	1

462	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. <i>Journal of Neurodevelopmental Disorders</i> , 2020 , 12, 24	4.6	8
461	Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept. <i>BMC Nephrology</i> , 2020 , 21, 354	2.7	6
460	Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMI. <i>Therapeutics and Clinical Risk Management</i> , 2020 , 16, 787-793	2.9	2
459	Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
458	Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1605-1611	4.3	10
457	Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). <i>PLoS ONE</i> , 2019 , 14, e0222730	2.7	6
456	Diagnostic Utility of Exome Sequencing for Kidney Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 2078	59.2	10
455	Pre-existing malignancies in renal transplant candidates-time to reconsider waiting times. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1292-1300	4.3	11
454	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. <i>PLoS ONE</i> , 2019 , 14, e0212023	3.7	26
453	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 393, 1937-1947	4.0	209
452	A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. <i>BMC Nephrology</i> , 2019 , 20, 36	2.7	3
451	Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. <i>American Journal of Transplantation</i> , 2019 , 19, 123-131	8.7	15
450	Perioperative antibiotic prophylaxis in renal transplantation: a single-center comparison between two regimens and a brief survey among the Eurotransplant renal transplantation centers. <i>World Journal of Urology</i> , 2019 , 37, 957-967	4	4
449	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1000-1008	4.3	21
448	Validation of the Living Kidney Donor Profile Index in a European cohort and comparison of long-term outcomes with US results. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1063-1070	4.3	9
447	Risks and benefits of everolimus. <i>Transplant International</i> , 2019 , 32, 1124-1126	3	
446	Charakterisierung von Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS) in Deutschland. <i>Der Nephrologe</i> , 2019 , 14, 496-504	0.1	0
445	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. <i>Frontiers in Neurology</i> , 2019 , 10, 821	4.1	12

444	Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
443	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2019 , 10, 705	4.1	13
442	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1056-1066	6.9	16
441	Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	4
440	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. <i>Frontiers in Neurology</i> , 2019 , 10, 1144	4.1	9
439	Pregnancy following kidney transplantation - impact on mother and graft function and focus on childrensMongitudinal development. <i>BMC Pregnancy and Childbirth</i> , 2019 , 19, 376	3.2	11
438	Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2338-2353	12.7	11
437	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 53-58	3.2	3
436	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 261-307	3.2	163
435	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. <i>Trials</i> , 2019 , 20, 37	2.8	35
434	Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. <i>Epilepsia Open</i> , 2019 , 4, 73-84	4	63
433	Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review. <i>European Urology Focus</i> , 2019 , 5, 508-517	5.1	8
432	Late Steroid Withdrawal Following ABO-Incompatible Renal Transplantation. <i>Transplantation Proceedings</i> , 2018 , 50, 72-78	1.1	1
431	Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1796-1803	4.6	18
430	Assessment of the Kidney Donor Profile Index in a European cohort. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1465-1472	4.3	27
429	Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients. <i>American Journal of Transplantation</i> , 2018 , 18, 1810-1814	8.7	18
428	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. <i>American Journal of Transplantation</i> , 2018 , 18, 1726-1734	8.7	31
427	High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 564-573	4.5	8

426	Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1699-1707	4.3	27
425	Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex. <i>Scientific Reports</i> , 2018 , 8, 953	4.9	8
424	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 563-573	4.3	24
423	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. <i>American Journal of Transplantation</i> , 2018 , 18, 2965-2976	8.7	9
422	Investigation of the physical and psychosocial outcomes after living kidney donation - a multicenter cohort study (SoLKiD - Safety of Living Kidney Donors). <i>BMC Nephrology</i> , 2018 , 19, 83	2.7	4
421	Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study. <i>Transplantation</i> , 2018 , 102, 1545-1552	1.8	33
420	Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf®) in kidney transplant patients in Germany: A multicenter, noninterventional study. <i>Clinical Transplantation</i> , 2018 , 32, e13142	3.8	12
419	Invited letter in response to "Predicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg?". <i>American Journal of Transplantation</i> , 2018 , 18, 523-524	8.7	2
418	European Association of Urology Guidelines on Renal Transplantation: Update 2018. <i>European Urology Focus</i> , 2018 , 4, 208-215	5.1	50
417	A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. <i>American Journal of Transplantation</i> , 2018 , 18, 2945-2954	8.7	29
416	MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection. <i>PLoS ONE</i> , 2018 , 13, e0201925	3.7	11
415	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , 2018 , 19, 154	2.7	2
414	Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. <i>Clinical Transplantation</i> , 2018 , 32, e13311	3.8	7
413	Prophylaxis and treatment of <i>Pneumocystis Jirovecii</i> pneumonia after solid organ transplantation. <i>Pharmacological Research</i> , 2018 , 134, 61-67	10.2	14
412	A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation. <i>PLoS ONE</i> , 2018 , 13, e0193569	3.7	5
411	Detecting Named Entities and Relations in German Clinical Reports. <i>Lecture Notes in Computer Science</i> , 2018 , 146-154	0.9	2
410	High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation. <i>Journal of Women's Health</i> , 2018 , 27, 394-398	3	4
409	Adjustment of target weight based on absolute blood volume reduces the frequency of intradialytic morbid events. <i>Hemodialysis International</i> , 2018 , 22, 254-260	1.7	12

408	The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. <i>European Urology</i> , 2018 , 73, 94-108	10.2	27
407	Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. <i>Transplantation Direct</i> , 2018 , 4, e380	2.3	12
406	Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2018 , 50, 3232-3241	1.1	9
405	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. <i>BMC Nephrology</i> , 2018 , 19, 237	2.7	9
404	The regulation of interferon type I pathway-related genes RSAD2 and ETV7 specifically indicates antibody-mediated rejection after kidney transplantation. <i>Clinical Transplantation</i> , 2018 , 32, e13429	3.8	5
403	SaO014USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i321-i321	4.3	1
402	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis. <i>PLoS ONE</i> , 2018 , 13, e0201005	3.7	12
401	Psychosocial Long-Term Impact of Donation on Kidney Living Donors - A Comparative Study of Two Major European Transplant Centres. <i>Transplantation</i> , 2018 , 102, S612	1.8	
400	Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2018 , 102, 2065-2071	1.8	15
399	FP713DE NOVO MALIGNANCIES AFTER KIDNEY TRANSPLANTATION: A LONG-TERM OBSERVATIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i286-i286	4.3	
398	Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation. <i>Transplantation</i> , 2017 , 101, 2165-2174	1.8	27
397	Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection. <i>Transplantation</i> , 2017 , 101, 2017-2025	1.8	4
396	Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation. <i>American Journal of Transplantation</i> , 2017 , 17, 3076-3086	8.7	75
395	Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide. <i>Transplantation</i> , 2017 , 101, 2545-2552	1.8	8
394	Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation. <i>Critical Care Medicine</i> , 2017 , 45, e941-e946	1.4	23
393	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1060-1070	4.3	26
392	Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 880-889	4.3	5
391	Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 216-223	4.3	47

390	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2017 , 92, 796-808	9.9	25
389	Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step. <i>Journal of Immunology Research</i> , 2017 , 2017, 6872046	4.5	9
388	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. <i>PLoS ONE</i> , 2017 , 12, e0180939	3.7	92
387	Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1601-1608	4.3	18
386	Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. <i>Transplantation Proceedings</i> , 2017 , 49, 1747-1756.e1	1.1	10
385	Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome. <i>Transplantation Proceedings</i> , 2017 , 49, 1757-1765	1.1	10
384	Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2636-2650	3.8	36
383	Transplanting HCV-Infected Kidneys into Uninfected Recipients. <i>New England Journal of Medicine</i> , 2017 , 377, 1103-4	59.2	13
382	Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops. <i>Transplantation</i> , 2017 , 101, 1887-1896	1.8	50
381	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals. <i>Transplantation</i> , 2017 , 101, 1875-1886	1.8	44
380	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. <i>Transplantation Proceedings</i> , 2017 , 49, 2269-2273	1.1	5
379	Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis. <i>Transplantation Proceedings</i> , 2017 , 49, 2256-2259	1.1	9
378	Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. <i>Transplantation Proceedings</i> , 2017 , 49, 2280-2284	1.1	2
377	Immunologic Long-term Outcomes of Living-Related Kidney Transplantations Depending on the Donor-Recipient Relationship. <i>Transplantation Proceedings</i> , 2017 , 49, 2265-2268	1.1	0
376	A novel tool for the identification of correlations in medical data by faceted search. <i>Computers in Biology and Medicine</i> , 2017 , 85, 98-105	7	7
375	Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. <i>Transplantation</i> , 2017 , 101, 2780-2788	1.8	7
374	Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis. <i>American Journal of Transplantation</i> , 2017 , 17, 819-823	8.7	4
373	Biomarkers in acute kidney injury - pathophysiological basis and clinical performance. <i>Acta Physiologica</i> , 2017 , 219, 554-572	5.6	144

372	Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. <i>Pediatric Nephrology</i> , 2017 , 32, 1137-1144	3.2	22
371	Development of Graft-Site Candidiasis in 3 Solid Organ Transplant Recipients from the Same Donor. <i>American Journal of Case Reports</i> , 2017 , 18, 777-781	1.3	3
370	Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). <i>PLoS ONE</i> , 2017 , 12, e0189132	3.7	8
369	Motivations, Challenges, and Attitudes to Self-management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 461-78	7.4	77
368	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: extension of a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 111-9	4.3	88
367	Secreted Frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 284-9	4.3	7
366	Immunosuppression and Results in Renal Transplantation. <i>European Urology Supplements</i> , 2016 , 15, 415-429	4.9	8
365	Experience with belatacept rescue therapy in kidney transplant recipients. <i>Transplant International</i> , 2016 , 29, 1184-1195	3	35
364	Clinical outcome of norovirus infection in renal transplant patients. <i>Clinical Transplantation</i> , 2016 , 30, 1283-1293	3.8	8
363	Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016 , 76, 612-619	2	4
362	Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. <i>Transplantation Direct</i> , 2016 , 2, e91	2.3	10
361	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 648-59	7.4	55
360	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1002-13	4.3	31
359	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 691-7	4.3	48
358	Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2519-32	15.9	118
357	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. <i>Clinical Nephrology</i> , 2016 , 85, 215-25	2.1	7
356	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. <i>Transplantation Direct</i> , 2016 , 2, e79	2.3	24
355	The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. <i>Clinical Transplantation</i> , 2016 , 30, 105-17	3.8	14

354	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S1-20	3.2	57
353	Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood. <i>Transplantation</i> , 2016 , 100, 898-907	1.8	22
352	Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 2143-2149	4.3	13
351	Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S43-9	3.2	5
350	Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangiomyomatosis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 958-70	3.8	20
349	Improved Left Ventricular Structure and Function After Successful Kidney Transplantation. <i>Kidney and Blood Pressure Research</i> , 2016 , 41, 701-709	3.1	30
348	Risk Evaluation and Outcome of Pneumocystis jirovecii Pneumonia in Kidney Transplant Patients. <i>Transplantation Proceedings</i> , 2016 , 48, 2924-2930	1.1	20
347	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 143-69	3.2	71
346	Immunosuppression in the elderly renal allograft recipient: a systematic review. <i>Transplantation Reviews</i> , 2016 , 30, 144-53	3.3	18
345	PD04-03 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TSC OR SLAM: FINAL LONG-TERM RESULTS FROM EXIST-2. <i>Journal of Urology</i> , 2016 , 195,	2.5	3
344	The Clinical Data Intelligence Project. <i>Informatik-Spektrum</i> , 2016 , 39, 290-300	0.3	5
343	Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1351-9	4.3	22
342	Feel stronger and younger all the time? Perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1531-40	4.3	13
341	Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. <i>Nephron</i> , 2016 , 134, 51-58	3.3	43
340	Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation. <i>Transplant Immunology</i> , 2016 , 39, 52-59	1.7	13
339	The selective biomarker IL-8 identifies IFTA after kidney transplantation in blood cells. <i>Transplant Immunology</i> , 2016 , 39, 18-24	1.7	4
338	LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. <i>Transplant International</i> , 2016 , 29, 603-11	3	17
337	Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. <i>American Journal of Transplantation</i> , 2015 , 15, 119-28	8.7	90

336	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. <i>Clinical Nephrology</i> , 2015 , 83, 11-21	2.1	30
335	Midterm echocardiographic follow-up of cardiac function after living kidney donation. <i>Clinical Nephrology</i> , 2015 , 83, 253-61	2.1	6
334	Advances in pharmacotherapy to treat kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1627-48	4	8
333	The need for minimization strategies: current problems of immunosuppression. <i>Transplant International</i> , 2015 , 28, 891-900	3	79
332	Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2015 , 19, 757-8	2.5	
331	Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 825-31	6.9	34
330	Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. <i>Journal of Nephrology</i> , 2015 , 28, 115-23	4.8	15
329	Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. <i>Transplant International</i> , 2015 , 28, 710-9	3	24
328	Need for optimized immunosuppression in elderly kidney transplant recipients. <i>Transplantation Reviews</i> , 2015 , 29, 237-9	3.3	27
327	Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation. <i>Transplant Immunology</i> , 2015 , 33, 176-84	1.7	1
326	PD35-10 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EFFICACY AND SAFETY AFTER 3.5 YEARS OF TREATMENT IN THE EXIST-2 STUDY. <i>Journal of Urology</i> , 2015 , 193,	2.5	2
325	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1086-96	3.8	10
324	Renal allograft loss caused by cardiorenal syndrome: frequency and diagnosis. <i>Transplantation</i> , 2015 , 99, 1208-15	1.8	7
323	The Relationship of the Severity and Category of Acute Rejection With Intimal Arteritis Defined in Banff Classification to Clinical Outcomes. <i>Transplantation</i> , 2015 , 99, e105-14	1.8	10
322	Suspended in a paradox? Patient attitudes to wait-listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies. <i>Transplant International</i> , 2015 , 28, 771-87	3	37
321	FP825IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii352-iii353	4.3	
320	FP834IMPACT OF PREGNANCIES ON IMMUNIZATION AND OUTCOME IN KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii356-iii356	4.3	
319	FP837BODY MASS INDEX (BMI) MISMATCH IN DECEASED KIDNEY DONATION IS AN INDEPENDENT RISK FACTOR FOR GRAFT FAILURE. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii357-iii357	4.3	

318	FP870HLA-DR MATCHING IMPROVES IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii367-iii368	4.3	
317	Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. <i>American Journal of Transplantation</i> , 2015 , 15, 1644-53	8.7	42
316	Strategies to increase the donor pool and access to kidney transplantation: an international perspective. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 217-22	4.3	57
315	Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte B-integrin Activation. <i>Transplantation</i> , 2015 , 99, 2593-7	1.8	28
314	Living Donor Transplantation: Long-Term Evolution Related to Age Matching. <i>Transplantation Proceedings</i> , 2015 , 47, 2346-50	1.1	1
313	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. <i>Transplant International</i> , 2014 , 27, 1192-204	3	4
312	Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. <i>Journal of Transplantation</i> , 2014 , 2014, 179705	2.3	4
311	Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 36.. <i>Transplantation</i> , 2014 , 98, 81	1.8	4
310	Conversion From Tacrolimus to Cyclosporine A Improves Glucose Metabolism in Patients With New Onset Diabetes After Transplantation: Interim Analysis of a Prospective and Randomized Study.. <i>Transplantation</i> , 2014 , 98, 95	1.8	2
309	Efficacy and Safety of Three Different Treatment Regimens in De Novo Renal Transplant Patients: Month 36 Follow-Up Results of HERAKLES Trial.. <i>Transplantation</i> , 2014 , 98, 81-82	1.8	2
308	Once-Daily Envarsus Demonstrates Comparable Efficacy and Safety to Twice-Daily Prograf: A Phase 3 Study for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients.. <i>Transplantation</i> , 2014 , 98, 116	1.8	
307	Two-Year Results of Envarsus (Once-Daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-Daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study.. <i>Transplantation</i> , 2014 , 98, 661-662	1.8	1
306	Rapid Attainment of Tacrolimus Trough Levels Early Post-Transplant Reduces Risk of Treatment Failure in De Novo Kidney Transplant Patients: A Covariate Analysis of a Phase 3 Double-Blind Study.. <i>Transplantation</i> , 2014 , 98, 459	1.8	
305	Post Hoc Analysis of ZEUS and HERAKLES, Two Prospective, Open-Label, Multicenter, Randomized Trials: Onset and Progression of Diabetes in Kidney Transplant Recipients On Cyclosporine Standard or Converted to CNI-Free or CNI-Low Everolimus Regimen.. <i>Transplantation</i> , 2014 , 98, 145-146	1.8	1
304	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29 Suppl 4, iv26-32	4.3	9
303	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2014 , 86, 1244-52	9.9	67
302	Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients. <i>Infection</i> , 2014 , 42, 981-9	5.8	14
301	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 361-72	4.1	26

300	Genetic polymorphisms in IL-2, IL-10, TGF- β 1, and IL-2RB and acute rejection in renal transplant patients. <i>Clinical Transplantation</i> , 2014 , 28, 649-55	3.8	17
299	Complement-binding anti-HLA antibodies and kidney transplantation. <i>New England Journal of Medicine</i> , 2014 , 370, 85-6	59.2	10
298	Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. <i>Clinical Transplantation</i> , 2014 , 28, 410-8	3.8	17
297	The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. <i>Transplant International</i> , 2014 , 27, 176-86	3	8
296	Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. <i>Transplant International</i> , 2014 , 27, 77-86	3	107
295	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29 Suppl 4, iv15-25	4.3	129
294	Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. <i>Antioxidants and Redox Signaling</i> , 2014 , 21, 2401-18	8.4	34
293	Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database. <i>Clinical Transplantation</i> , 2014 , 28, 67-79	3.8	10
292	The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. <i>Transplantation</i> , 2014 , 97, 1146-54	1.8	43
291	The preferences and perspectives of nephrologists on patients' access to kidney transplantation: a systematic review. <i>Transplantation</i> , 2014 , 98, 682-91	1.8	30
290	Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 71-9	3.2	62
289	Fate of finally transplanted deceased donor kidneys initially rejected at other kidney transplantation centers. <i>Urologia Internationalis</i> , 2014 , 93, 474-81	1.9	5
288	Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. <i>American Journal of Transplantation</i> , 2014 , 14, 2796-806	8.7	68
287	Hauttumoren nach Organtransplantation. <i>Der Nephrologe</i> , 2013 , 8, 239-246	0.1	
286	Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution. <i>World Journal of Urology</i> , 2013 , 31, 947-52	4	5
285	Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: computed tomography angiography versus magnetic resonance angiography in 118 patients. <i>World Journal of Urology</i> , 2013 , 31, 983-90	4	21
284	Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013 , 49, 243-54	2.9	916
283	Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013 , 49, 255-65	2.9	553

282	Combined standard and novel immunosuppressive substances affect B-lymphocyte function. <i>International Immunopharmacology</i> , 2013 , 15, 718-25	5.8	9
281	Novel views on new-onset diabetes after transplantation: development, prevention and treatment. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 550-66	4.3	78
280	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 381, 817-24	4.0	583
279	New perspectives of immunosuppression. <i>Transplantation Proceedings</i> , 2013 , 45, 1224-31	1.1	8
278	Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors. <i>Transplant International</i> , 2013 , 26, 1208-16	3	36
277	Frequency and long-term outcomes of post-transplant hypophosphatemia after kidney transplantation. <i>Transplant International</i> , 2013 , 26, e94-6	3	8
276	Sotrastaurin. <i>Der Nephrologe</i> , 2013 , 8, 428-430	0.1	
275	Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. <i>American Journal of Transplantation</i> , 2013 , 13, 1746-56	8.7	33
274	Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. <i>American Journal of Transplantation</i> , 2013 , 13, 1757-68	8.7	27
273	Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. <i>Acta Physiologica</i> , 2013 , 207, 663-72	5.6	156
272	Belatacept utilization recommendations: an expert position. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 111-22	4.1	11
271	Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. <i>American Journal of Transplantation</i> , 2013 , 13, 760-9	8.7	68
270	Treatment with sirolimus is associated with less weight gain after kidney transplantation. <i>Transplantation</i> , 2013 , 96, 480-6	1.8	7
269	A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. <i>Clinical Nephrology</i> , 2013 , 79, 421-31	2.1	7
268	Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 276-83	7.4	71
267	Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. <i>American Journal of Transplantation</i> , 2012 , 12, 1192-8	8.7	193
266	Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. <i>American Journal of Transplantation</i> , 2012 , 12, 1528-40	8.7	66
265	Weight gain in long-term survivors of kidney or liver transplantation--another paradigm of sarcopenic obesity?. <i>Nutrition</i> , 2012 , 28, 378-83	4.8	55

264	Tacrolimus only for breakfast □ <i>Transplant International</i> , 2012 , 25, 274-5	3	2
263	Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. <i>Transplant International</i> , 2012 , 25, 1106-16	3	30
262	Immunosuppressive Potential and Side Effects of Everolimus. <i>American Journal of Transplantation</i> , 2012 , 12, 2563-2563	8.7	1
261	Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the TranCept STAY study. <i>Clinical Transplantation</i> , 2012 , 26, 919-26	3.8	6
260	Non-invasive imaging of living kidney donors: intraindividual comparison of multislice computed tomography angiography with magnetic resonance angiography. <i>Clinical Transplantation</i> , 2012 , 26, E412-7	3.8	13
259	Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. <i>American Journal of Transplantation</i> , 2012 , 12, 2446-56	8.7	112
258	Inosine 5Monophosphate dehydrogenase activity as a biomarker in the field of transplantation. <i>Clinica Chimica Acta</i> , 2012 , 413, 1391-7	6.2	24
257	Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. <i>Drugs</i> , 2012 , 72, 1335-54	12.1	17
256	Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. <i>Transplantation Reviews</i> , 2012 , 26, 233-40	3.3	14
255	Generika in der Nierentransplantation. <i>Der Nephrologe</i> , 2012 , 7, 233-234	0.1	
254	Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 913-22	2.8	16
253	Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 1246-51	4.3	92
252	An evaluation of sirolimus in renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1337-56	5.5	23
251	Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(□)) in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 423-8	4.3	61
250	A cardiovascular risk calculator for renal transplant recipients. <i>Transplantation</i> , 2012 , 94, 57-62	1.8	51
249	Pretransplant PRA and Long-Term Outcomes of Kidney Transplant Recipients. <i>Transplantation</i> , 2012 , 94, 1076	1.8	
248	About incidence and timing of donor-specific antibodies after graft nephrectomy. <i>Transplantation</i> , 2012 , 93, 865-6	1.8	3
247	Clindamycin-Primaquine Is Safe in Treating Pneumocystis Pneumonia in Renal Transplant Patients but Appears to Be Less Effective than Trimethoprim/Sulfamethoxazole. <i>Transplantation</i> , 2012 , 94, 547	1.8	

246	The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation. <i>Transplantation</i> , 2012 , 94, 241	1.8	
245	Determinants of Outcome after KTX in Elderly Patients. <i>Transplantation</i> , 2012 , 94, 922	1.8	
244	Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: The HERAKLES Study. <i>Transplantation</i> , 2012 , 94, 993	1.8	1
243	The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation. <i>Transplantation</i> , 2012 , 94, 1044	1.8	
242	Determinants and Duration of Hospitalisations after KTX in Elderly Patients. <i>Transplantation</i> , 2012 , 94, 918	1.8	
241	Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial. <i>Transplantation</i> , 2012 , 94, 993	1.8	1
240	Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 3 Year Data of the APOLLO Trial. <i>Transplantation</i> , 2012 , 94, 994	1.8	1
239	A Phase III Randomized Trial of Conversion to Once-Daily Extended Release Meltdose [®] Tacrolimus Tablets (LCP-Tacro [®]) from Twice-Daily Tacrolimus Capsules (Prograf [®]): Efficacy Results from an Analysis of Specific Patient Sub-Populations. <i>Transplantation</i> , 2012 , 94, 984	1.8	
238	Effects of Sotrastaurin, Mycophenolic Acid and Everolimus on Human B-Lymphocyte Function and Activation. <i>Transplantation</i> , 2012 , 94, 1117	1.8	
237	Pre-Operative Assessment of Living Renal Transplant Donors with State-Of-The-Art Imaging Modalities: Computed Tomography Angiography vs. Magnetic Resonance Angiography in 118 Patients. <i>Transplantation</i> , 2012 , 94, 187	1.8	
236	Sotrastaurin + Reduced-Exposure Tacrolimus Prevents Acute Rejection and Preserves Renal Function after De Novo Kidney Transplantation - 12 Month Results. <i>Transplantation</i> , 2012 , 94, 980	1.8	
235	Efficacy and Safety of Three Different Treatment Regimens in de Novo Renal Transplant Patients: Results of the HERAKLES Trial. <i>Transplantation</i> , 2012 , 94, 995	1.8	1
234	Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT). <i>Transplantation</i> , 2012 , 94, 996	1.8	1
233	IMP-Dehydrogenase in Erythrocytes for Detection of Non-Adherence to MPA Therapy. <i>Transplantation</i> , 2012 , 94, 1191	1.8	
232	Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: Results from EXIST-2.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 356-356	2.2	3
231	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011 , 13, R75	5.7	136
230	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. <i>Lancet, The</i> , 2011 , 377, 837-47	4.0	294
229	Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. <i>Transplantation</i> , 2011 , 91, 779-85	1.8	24

228	Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. <i>Transplantation</i> , 2011 , 92, 321-7	1.8	9
227	Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. <i>Transplantation</i> , 2011 , 91, 317-22	1.8	15
226	Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 179-84	1.9	40
225	Biomarkers of over-immunosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 316-22	6.1	30
224	Accumulation of elderly ESRD patients with blood group O on the waiting list. <i>Transplant International</i> , 2011 , 24, e83-4	3	5
223	Age-related penetrance of hereditary atypical hemolytic uremic syndrome. <i>Annals of Human Genetics</i> , 2011 , 75, 639-47	2.2	24
222	Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. <i>American Journal of Transplantation</i> , 2011 , 11, 1444-55	8.7	65
221	Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. <i>Transplantation Proceedings</i> , 2011 , 43, 1641-6	1.1	13
220	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011 , 25, 58-64	3.3	52
219	Belatacept. <i>Der Nephrologe</i> , 2011 , 6, 166-168	0.1	
218	Diets and enteral supplements for improving outcomes in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2011 , 7, 369-84	14.9	119
217	Desensitization of HLA-incompatible kidney recipients. <i>New England Journal of Medicine</i> , 2011 , 365, 1643; author reply 1644-5	59.2	7
216	Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 103-13	5.5	26
215	How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 155-64	3.2	16
214	Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. <i>Annals of Human Genetics</i> , 2010 , 74, 17-26	2.2	55
213	Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2010 , 69, 346-57	3.8	49
212	Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. <i>Transplant International</i> , 2010 , 23, 1191-204	3	75
211	Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 503-11	6.9	36

210	The blood group O problem in kidney transplantation--time to change?. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 1998-2004	4.3	32
209	Effects of the new immunosuppressive agent AEB071 on human immune cells. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2159-67	4.3	16
208	Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 703-8	6.9	51
207	Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 283-92	4.3	7
206	IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL. <i>Transplantation</i> , 2010 , 90, 109	1.8	2
205	De novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression. <i>Case Reports in Dermatology</i> , 2010 , 2, 32-35	1.1	3
204	Comparison of first and second kidney transplants from the same deceased donor. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 4055-61	4.3	16
203	AN INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS RESULTS IN IMPROVED EFFICACY WITHOUT COMPROMISING SAFETY: 1 YEAR FOLLOW-UP RESULTS. <i>Transplantation</i> , 2010 , 90, 611	1.8	
202	Everolimus in patients with autosomal dominant polycystic kidney disease. <i>New England Journal of Medicine</i> , 2010 , 363, 830-40	59.2	430
201	Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. <i>Transplantation Proceedings</i> , 2010 , 42, 1325-8	1.1	8
200	Why rejections are not biopsy proven: frequency and reasons. <i>Transplantation Proceedings</i> , 2010 , 42, 4509-12	1.1	2
199	Enteric-coated mycophenolate sodium. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 981-94	4.1	34
198	Biomarkers as a tool for management of immunosuppression in transplant patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 560-72	3.2	46
197	RENAL FUNCTION OF AN EVEROLIMUS BASED THERAPY AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS ONE YEAR AFTER CONVERSION. <i>Transplantation</i> , 2010 , 90, 612	1.8	
196	Target enzyme activity as a biomarker for immunosuppression. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 257-60	3.2	6
195	Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. <i>Transplantation</i> , 2010 , 89, 595-9	1.8	38
194	Betreuung des Patienten auf der Warteliste und nach Transplantation. <i>Diabetologe</i> , 2010 , 6, 469-476	0.2	
193	Immunsuppression: neue Entwicklungen. <i>Der Nephrologe</i> , 2010 , 5, 133-141	0.1	

192	Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. <i>American Journal of Transplantation</i> , 2010 , 10, 571-81	8.7	69
191	Outcomes of transplanting deceased-donor kidneys between elderly donors and recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 37-40	12.7	36
190	The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, F218-27	4.3	15
189	Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 936-42	6.9	22
188	Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. <i>American Journal of Transplantation</i> , 2009 , 9, 2331-7	8.7	36
187	UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 86, 319-27	6.1	97
186	Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 218-23	3.2	16
185	Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. <i>Transplantation</i> , 2009 , 87, 1505-13	1.8	272
184	A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. <i>Transplantation</i> , 2009 , 88, 1101-8	1.8	38
183	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 626-34	1.9	63
182	Improved assay for the nonradioactive determination of inosine 5Mnophosphate dehydrogenase activity in peripheral blood mononuclear cells. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 351-9	3.2	47
181	Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 585-91	3.2	24
180	Attitude to nephrolithiasis in the potential living kidney donor: a survey of the German kidney transplant centers and review of the literature. <i>Clinical Transplantation</i> , 2008 , 22, 476-83	3.8	11
179	Cross-over kidney transplantation with simultaneous laparoscopic living donor nephrectomy: initial experience. <i>European Urology</i> , 2008 , 53, 1074-8	10.2	4
178	Immunosuppression in renal transplantation: some aspects for the modern era. <i>Transplantation Reviews</i> , 2008 , 22, 241-51	3.3	17
177	Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 827-38	6.2	66
176	Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation. <i>Transplant Immunology</i> , 2008 , 18, 319-23	1.7	15
175	Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. <i>Cytokine</i> , 2008 , 42, 306-14		10

174	Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 294, F440-9	4.3	54
173	Dialyse und Schwangerschaft [Eine Fallserie von fünf Schwangeren unter intensivierter Dialyse. <i>Dialyse Aktuell</i> , 2008 , 12, 292-298	0.1	
172	Arrival time parametric imaging: a new ultrasound technique for quantifying perfusion of kidney grafts. <i>Ultraschall in Der Medizin</i> , 2008 , 29, 418-23	3.8	20
171	Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. <i>Transplantation</i> , 2008 , 86, 1043-51	1.8	209
170	AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 439-44	3.2	39
169	Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. <i>Transplant International</i> , 2008 , 21, 152-5	3	22
168	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 339-48	1.9	96
167	Pharmacokinetic principles of immunosuppressive drugs. <i>Annals of Transplantation</i> , 2008 , 13, 5-10	1.4	2
166	Current perspectives on FTY720. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 505-18	5.9	19
165	Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. <i>Clinical Transplantation</i> , 2007 , 21, 117-25	3.8	12
164	Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. <i>American Journal of Transplantation</i> , 2007 , 7, 888-98	8.7	91
163	Lessons from the CAESAR Study: calcineurin inhibitors--can we live with them and can we live without them. <i>American Journal of Transplantation</i> , 2007 , 7, 495-6	8.7	5
162	Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. <i>American Journal of Transplantation</i> , 2007 , 7, 1506-14	8.7	458
161	Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. <i>American Journal of Transplantation</i> , 2007 , 7, 1822-31	8.7	61
160	No evidence for a relationship between infiltrates in renal protocol biopsies and outcome. <i>American Journal of Transplantation</i> , 2007 , 7, 2637-8; author reply 2639-40	8.7	3
159	Suggested guidelines for reporting clinical results in transplantation trials. <i>Transplantation Reviews</i> , 2007 , 21, 136-142	3.3	0
158	Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. <i>World Journal of Urology</i> , 2007 , 25, 325-32	4	11
157	S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, F1761-70	4.3	21

156	The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 2354-8	4.3	14
155	Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 850-9	2.9	21
154	Pregnancy on intensified hemodialysis: fetal surveillance and perinatal outcome. <i>Fetal Diagnosis and Therapy</i> , 2007 , 22, 289-93	2.4	22
153	Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. <i>Transplantation</i> , 2007 , 83, 417-24	1.8	67
152	Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 77-86	3.2	56
151	Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 381-4	3.2	29
150	Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. <i>Transplantation Proceedings</i> , 2007 , 39, 1386-91	1.1	18
149	Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. <i>International Immunopharmacology</i> , 2007 , 7, 88-95	5.8	7
148	Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. <i>Clinical Nephrology</i> , 2007 , 67, 164-75	2.1	13
147	Lebendnientransplantation. <i>Der Nephrologe</i> , 2006 , 1, 63-70	0.1	1
146	Prävention der kontrastmittelinduzierten Nephropathie. <i>Clinical Research in Cardiology Supplements</i> , 2006 , 1, 133-138	3.1	
145	FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. <i>American Journal of Transplantation</i> , 2006 , 6, 2912-21	8.7	129
144	FTY720 (fingolimod) in renal transplantation. <i>Clinical Transplantation</i> , 2006 , 20 Suppl 17, 17-24	3.8	82
143	Improved diagnosis of early kidney allograft dysfunction by ultrasound with echo enhancer—a new method for the diagnosis of renal perfusion. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 2921-9	4.3	42
142	Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A. <i>Clinical Immunology</i> , 2006 , 119, 59-66	9	2
141	FK506, transforming growth factor-beta1 and mesangial matrix synthesis: parallels and differences compared with cyclosporine A. <i>Cytokine</i> , 2006 , 33, 59-65	4	6
140	Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation. <i>Transplantation Proceedings</i> , 2006 , 38, 2292-4	1.1	9
139	Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. <i>Transplantation Proceedings</i> , 2006 , 38, 2856-9	1.1	17

138	Reporting of rejection after renal transplantation in large immunosuppressive trials: biopsy-proven, clinical, presumed, or treated rejection?. <i>Transplantation</i> , 2006 , 81, 655-9	1.8	11
137	Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. <i>Transplantation</i> , 2006 , 82, 55-61	1.8	67
136	Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. <i>Transplantation</i> , 2006 , 82, 1004-12	1.8	57
135	Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 220-2	4.3	36
134	Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 319-28	4.3	25
133	Limitations of C2 monitoring in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 1463-70	4.3	20
132	Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. <i>Transplantation Proceedings</i> , 2005 , 37, 1601-4	1.1	40
131	Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. <i>Transplantation Proceedings</i> , 2005 , 37, 912-5	1.1	19
130	Accurate prediction of kidney allograft outcome based on creatinine course in the first 6 months posttransplant. <i>Transplantation Proceedings</i> , 2005 , 37, 731-3	1.1	5
129	Laparoscopic versus open donor nephrectomy in Germany: impact on donor health-related quality of life and willingness to donate. <i>Transplantation Proceedings</i> , 2005 , 37, 2011-5	1.1	29
128	Differences in reporting of acute rejections between American and European publications of large immunosuppressive trials impair comparability of study results. <i>Transplantation Proceedings</i> , 2005 , 37, 2048-50	1.1	
127	Novel mediators of FTY720 in human lymphocytes. <i>Transplantation</i> , 2005 , 79, 492-5	1.8	10
126	Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 781-91	2.9	10
125	Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. <i>Transplantation</i> , 2005 , 79, 807-14	1.8	197
124	FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 1268-78	2.9	30
123	Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1)-mediated pathway and vascular oxidative injury in older-age rat renal transplants. <i>Kidney International</i> , 2005 , 67, 1583-94	9.9	14
122	Use of Neoral C monitoring: a European consensus. <i>Transplant International</i> , 2005 , 18, 768-78	3	52
121	Pharmacokinetic principles of immunosuppressive drugs. <i>American Journal of Transplantation</i> , 2005 , 5, 207-17	8.7	53

120	Proposal for guidelines for publication of randomized trials in the American Journal of Transplantation. <i>American Journal of Transplantation</i> , 2005 , 5, 644-7	8.7	7
119	Enteric-Coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF), it is Better to Have the Choice. <i>American Journal of Transplantation</i> , 2005 , 5, 1165-1166	8.7	3
118	Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. <i>American Journal of Transplantation</i> , 2005 , 5, 2521-30	8.7	175
117	Effect of pregnancy on long-term kidney function in renal transplant recipients treated with cyclosporine and with azathioprine. <i>American Journal of Transplantation</i> , 2005 , 5, 2732-9	8.7	59
116	The use of contrast-enhanced US in renal transplant: first results and potential clinical benefit. <i>European Radiology, Supplement</i> , 2005 , 15 Suppl 5, E109-16		33
115	A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 2537-42	4.3	68
114	Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. <i>New England Journal of Medicine</i> , 2005 , 352, 558-69	59.2	622
113	Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients. <i>Kidney and Blood Pressure Research</i> , 2004 , 27, 186-90	3.1	6
112	Review of the immunosuppressant enteric-coated mycophenolate sodium. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1333-45	4	71
111	The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 215-22	4.3	34
110	Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2606-14	4.3	39
109	The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2630-3	4.3	43
108	No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2846-51	4.3	7
107	MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 548-53	3.8	65
106	FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. <i>Kidney International</i> , 2004 , 65, 1076-83	9.9	44
105	Reports of large immunosuppression trials in kidney transplantation: room for improvement. <i>American Journal of Transplantation</i> , 2004 , 4, 738-43	8.7	26
104	Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. <i>American Journal of Transplantation</i> , 2004 , 4, 1869-75	8.7	210
103	Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. <i>American Journal of Transplantation</i> , 2004 , 4, 2045-51	8.7	119

102	Testosterone concentrations and sirolimus in male renal transplant patients. <i>American Journal of Transplantation</i> , 2004 , 4, 130-1	8.7	75
101	Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. <i>American Journal of Transplantation</i> , 2004 , 4, 237-43	8.7	213
100	Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 923-6	7.4	19
99	Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 330-40	6.1	97
98	Impact of cyclosporine on the development of immunosuppressive therapy. <i>Transplantation Proceedings</i> , 2004 , 36, 130S-134S	1.1	12
97	Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. <i>Transplantation Proceedings</i> , 2004 , 36, 524S-527S	1.1	11
96	FTY720: early clinical experience. <i>Transplantation Proceedings</i> , 2004 , 36, 544S-548S	1.1	18
95	FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. <i>Transplantation</i> , 2004 , 77, 1424-32	1.8	13
94	Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. <i>Transplantation</i> , 2004 , 78, 1204-11	1.8	66
93	Quality of life of living kidney donors in Germany: a survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 questionnaires. <i>Transplantation</i> , 2004 , 78, 864-72	1.8	81
92	FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 702-13	4.3	38
91	IMPACT OF DACLIZUMAB AND LOW DOSE CYCLOSPORINE IN COMBINATION WITH MYCOPHENOLATE MOFETIL AND STEROIDS ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2004 , 78, 280-281	1.8	2
90	Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 163-72	2.9	33
89	Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem?. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 448-9	4.3	18
88	Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 819-22	4.3	132
87	MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 1101-7	2.9	55
86	Gadolinium-enhanced three-dimensional magnetic resonance angiography versus conventional digital subtraction angiography: which modality is superior in evaluating living kidney donors?. <i>Transplantation</i> , 2003 , 76, 1000-2	1.8	22
85	Evaluating candidates for kidney transplantation: some recommendations still lack convincing clinical evidence. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 621-2; author reply 622	4.3	2

84	Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. <i>American Journal of Transplantation</i> , 2003 , 3, 846-54	8.7	85
83	Old-for-old kidney allocation allows successful expansion of the donor and recipient pool. <i>American Journal of Transplantation</i> , 2003 , 3, 1434-9	8.7	97
82	"Old-for-old" cadaveric renal transplantation: surgical findings, perioperative complications and outcome. <i>European Urology</i> , 2003 , 44, 701-8	10.2	45
81	Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2003 , 55, 203-11	3.8	122
80	The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2003 , 55, 368-74	3.8	102
79	20-year experience with elderly donors in living renal transplantation. <i>Transplantation Proceedings</i> , 2003 , 35, 2855-7	1.1	11
78	Living donor nephrectomy--no impact of genetic relationship. <i>Transplantation Proceedings</i> , 2003 , 35, 2860-2	1.1	1
77	The immunosuppressive potential of misoprostol--efficacy and variability. <i>Clinical Immunology</i> , 2003 , 109, 288-94	9	6
76	Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. <i>Transplantation Proceedings</i> , 2003 , 35, 2104-5	1.1	18
75	Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells. <i>Cytokine</i> , 2003 , 22, 189-93	4	7
74	Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003 , 41, 470-6	2	43
73	Cyclosporin C2hour monitoring after renal transplantation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003 , 41, 477-81	2	2
72	Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003 , 41, 482-7	2	9
71	Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003 , 41, 488-91	2	7
70	Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. <i>Pharmacotherapy</i> , 2002 , 22, 154-9	5.8	65
69	Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 440, 648-54	5.1	5
68	Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. <i>Hepatology</i> , 2002 , 35, 466-77	11.2	69
67	Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 1310-7	4.3	37

66	Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 1568-77	4.3	40
65	Recognition of critical situations from time series of laboratory results by case-based reasoning. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2002 , 9, 520-8	8.6	16
64	Successful steroid withdrawal at the end of the 1st year after renal transplantation in mycophenolate mofetil-treated patients. <i>Transplantation Proceedings</i> , 2002 , 34, 1700-2	1.1	4
63	Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. <i>Transplantation Proceedings</i> , 2002 , 34, 1703-5	1.1	11
62	Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2002 , 34, 1738-9	1.1	17
61	Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. <i>Transplantation Proceedings</i> , 2002 , 34, 1594-6	1.1	2
60	Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. <i>Transplantation Proceedings</i> , 2002 , 34, 1745-7	1.1	9
59	Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2002 , 34, 1748-50	1.1	23
58	Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience. <i>Transplantation Proceedings</i> , 2002 , 34, 1815-6	1.1	12
57	Relevance and meaning of prostate cancer in kidney transplantation. <i>Transplantation Proceedings</i> , 2002 , 34, 2225-6	1.1	6
56	FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. <i>Transplantation Proceedings</i> , 2002 , 34, 2242-3	1.1	7
55	Laparoscopic donor nephrectomy in Germany. <i>Transplantation Proceedings</i> , 2002 , 34, 3099-101	1.1	9
54	First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 1073-1083	12.7	231
53	Non-radioactive determination of inosine 5-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. <i>Clinical Biochemistry</i> , 2001 , 34, 543-9	3.5	74
52	Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2001 , 33, 3102-3	1.1	8
51	Pharmacodynamic monitoring of lymphocyte proliferation and TGF-beta 1 expression at cyclosporine a (CyA) trough levels (C(0)) and 2 hours after intake (C(2)) of CyA in human renal allograft recipients. <i>Transplantation Proceedings</i> , 2001 , 33, 3148-50	1.1	8
50	Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. <i>Transplantation Proceedings</i> , 2001 , 33, 3234-5	1.1	35
49	Steroid withdrawal in long-term cyclosporine A treated patients using mycophenolate mofetil: a prospective randomized pilot study. <i>Transplantation Proceedings</i> , 2001 , 33, 3250-2	1.1	4

48	Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. <i>Transplantation Proceedings</i> , 2001 , 33, 3313-5	1.1	8
47	Case-based reasoning algorithm for kidney transplant monitoring. <i>Transplantation Proceedings</i> , 2001 , 33, 3331-3	1.1	0
46	Prostaglandin E(1) inhibits cyclosporine A-induced upregulation of transforming growth factor-beta 1 in rat mesangial cells. <i>Transplantation Proceedings</i> , 2001 , 33, 3342-4	1.1	2
45	Laparoscopic kidney harvesting for living donor kidney transplantation--one year follow-up of the initial 15 patients. <i>Transplantation Proceedings</i> , 2001 , 33, 3791-2	1.1	2
44	CC chemokine receptor 5 and renal-transplant survival. <i>Lancet, The</i> , 2001 , 357, 1758-61	4.0	263
43	A Web-Based Electronic Patient Record System as a Means for Collection of Clinical Data. <i>Lecture Notes in Computer Science</i> , 2001 , 198-205	0.9	3
42	Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers. <i>Transplantation</i> , 2000 , 70, 1492-7	1.8	28
41	Pharmacodynamic monitoring of mycophenolate mofetil. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 1213-6	5.9	52
40	Age-matching in renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15, 696-700	4.3	93
39	TNF-alpha and IL-1alpha induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers. <i>Cytokine</i> , 2000 , 12, 986-91	4	63
38	Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. <i>American Journal of Kidney Diseases</i> , 2000 , 35, E12	7.4	13
37	RE: SUCCESSFUL LIVING RELATED KIDNEY TRANSPLANTATION DESPITE RENAL ANGIOMYOLIPOMA IN SITU. <i>Journal of Urology</i> , 2000 , 163, 924-924	2.5	
36	Renal failure from diabetic glomerulosclerosis three decades after allograft transplantation. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 974-6	4.3	
35	Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required?. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 1036-8	4.3	29
34	Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 694-703	3.8	70
33	Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 65, 251-61	6.1	121
32	De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 556-9	7.4	68
31	Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. <i>American Journal of Kidney Diseases</i> , 1999 , 34, e9	7.4	26

30	Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. <i>Transplantation Proceedings</i> , 1999 , 31, 1382-3	1.1	2
29	SUCCESSFUL LIVING RELATED KIDNEY TRANSPLANTATION DESPITE RENAL ANGIOMYOLIPOMA IN SITU. <i>Journal of Urology</i> , 1999 , 162, 480-481	2.5	12
28	HUMAN SAFETY AND PHARMACOLOGY OF FTY 720. <i>Transplantation</i> , 1999 , 67, S153	1.8	9
27	SUCCESSFUL STEROID WITHDRAWAL DURING THE FIRST YEAR AFTER RENAL TRANSPLANTION IN MYCOPHENOLATE MOFETIL AND CYCLOSPORINE TREATED PATIENTS. <i>Transplantation</i> , 1999 , 67, S160	1.8	3
26	HUMAN PHARMACOKINETICS OF FTY 720. <i>Transplantation</i> , 1999 , 67, S204	1.8	8
25	Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. <i>Transplant International</i> , 1999 , 12, 283-7	3	2
24	Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. <i>Transplant International</i> , 1998 , 11, 53-57	3	8
23	Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. <i>Transplantation Proceedings</i> , 1998 , 30, 1190-1	1.1	14
22	Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. <i>Transplantation Proceedings</i> , 1998 , 30, 1238-9	1.1	2
21	Antibody therapy in steroid-resistant rejection. <i>Transplantation Proceedings</i> , 1998 , 30, 1778-9	1.1	11
20	Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. <i>Transplantation Proceedings</i> , 1998 , 30, 1780-1	1.1	3
19	Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. <i>Transplantation Proceedings</i> , 1998 , 30, 2083-5	1.1	9
18	The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. <i>Transplantation Proceedings</i> , 1998 , 30, 2195-7	1.1	58
17	Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. <i>Transplantation Proceedings</i> , 1998 , 30, 2229	1.1	2
16	Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. <i>Transplant International</i> , 1998 , 11, 53-7	3	3
15	Interleukin-6 expression after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 753-9	4.3	56
14	Differing proteinuria control with cyclosporin and tacrolimus. <i>Lancet, The</i> , 1997 , 349, 330	4.0	12
13	Hypertension in patients after renal transplantation. <i>Transplantation Proceedings</i> , 1997 , 29, 209-11	1.1	33

12	Interleukin-8 expression in patients after renal transplantation. <i>American Journal of Kidney Diseases</i> , 1997 , 29, 871-80	7.4	29
11	Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. <i>Kidney International</i> , 1997 , 52, 733-41	9.9	11
10	The influence of age on outcome after renal transplantation. <i>Geriatric Nephrology and Urology</i> , 1997 , 7, 137-46		15
9	Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11, 165-172	4.3	16
8	The diagnostic value of GM-CSF and IL-6 determinations in patients after renal transplantation. <i>Transplant International</i> , 1994 , 7 Suppl 1, S97-101	3	9
7	Interleukin 6 is an autocrine growth factor for mesangial cells. <i>Kidney International</i> , 1990 , 38, 249-57	9.9	152
6	Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients		2
5	Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients		1
4	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis		4
3	Diagnostic accuracy of a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior nasal swabs		2
2	Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients		12
1	B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant Recipients		1